Navigation Links
Actavis Receives Approval for Irinotecan Hydrochloride Injection; Extends US Portfolio with First Injectable Product
Date:2/28/2008

MORRISTOWN, N.J., Feb. 28 /PRNewswire/ -. Actavis Group, the international generic pharmaceuticals company, has received approval for Irinotecan Hydrochloride Injection from the U.S. Food & Drug Administration. Distribution of the product will begin immediately.

Irinotecan Hydrochloride Injection, the generic equivalent to Pfizer's Camptosar(R) will be available in 40 mg/2 mL and 100 mg/ 5 mL sizes and is used in the treatment of patients with metastatic carcinoma of the colon or rectum. Annual sales of Irinotecan Hydrochloride Injection in the United States were approximately US$556 million for the twelve months ending December 2007 according to IMS Health data.

Doug Boothe, Executive Vice President of US Commercial & Administration, said: "The launch of Irinotecan marks the expansion of Actavis' US portfolio into the injectable pharmaceuticals arena. Actavis has set its sights firmly on the hospital sector and currently has around 300 pending applications worldwide for injectable medicines. Furthermore, Actavis' ambitious pipeline comprises more than 60 new injectable projects, developed both internally and through established relationships with other developers."

Actavis currently markets over 50 hospital products worldwide, with a focus on oncology products and a growing range of anti-infectives, local anesthetics and analgesics.

About Actavis

Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. With headquarters in Iceland, Actavis has operations in 40 countries, with 11,000 employees. The United States is the company's single largest market. Actavis' U.S. operations are located in New Jersey, Maryland, North Carolina and Florida.

More information about Actavis in the United States can be found at http://www.actavis.us.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis. By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability.


'/>"/>
SOURCE Actavis Group
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
4. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
5. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
6. IsoTis Receives FDA Clearance for Accell Family of Products
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2017)... ... , ... It wasn’t just the San Diego temps that soared this summer. ... has had a record-breaking number of guests for corporate cooking challenges, team events and ... company outings, family get-togethers, anniversaries and milestone birthdays. While all groups gathered in ...
(Date:9/12/2017)... ... 2017 , ... September 15, 2017. Pittsburgh, PA. The ... the Department of Surgery and Cancer and Director of the MRC-NIHR National Phenome ... His presentation, “Analytical Science in Precision Medicine: Facing the Challenges of the 21st ...
(Date:9/12/2017)... ... 2017 , ... Facet Life Sciences, a leading provider of development solutions (software ... PhD has joined the company’s Board of Directors. , Dr. Massa brings 38 ... Most recently he served as VP and Head of Global Regulatory Operations at Sanofi. ...
(Date:9/12/2017)... ... September 11, 2017 , ... As part of BD’s ... BD is sponsoring an educational webinar in recognition of World Sepsis Day ... estimated five million deaths annually, is preventable and treatable through increased awareness and ...
Breaking Biology Technology:
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:3/30/2017)... YORK , March 30, 2017 Trends, ... type (physiological and behavioral), by technology (fingerprint, AFIS, iris ... voice recognition, and others), by end use industry (government ... and immigration, financial and banking, and others), and by ... Europe , Asia Pacific , ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):